Ipsen is a global specialty driven pharmaceutical company with total sales exceeding . billion in . Ipsen s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology, endocrinology and uro oncology. Moreover, the Group has an active policy of partnerships. R amp D is focused on innovative and differentiated technological patient driven platforms, peptides and toxins. In , R amp D expenditure totaled close to million, representing more than of Group sales. The Group has total worldwide staff of close to , employees.
Quote | Ipsen SA ADR (OTCMKTS:IPSEY)
Last: | $30.28 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $30.28 |
High: | $0 |
Low: | $0 |
Volume: | 343 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Ipsen SA ADR (OTCMKTS:IPSEY)
2024-07-02 03:34:12 ET More on Ipsen S.A. Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen gains accelerated approval for elafibranor for rare liver disease Ipsen and Marengo Therapeutics announce second strategic partnership ...
2024-06-10 17:33:20 ET More on Ipsen Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors Ipsen and Marengo Therapeutics announce second strategic partnership Ipsen S.A. reports Q1 results; reaffirms full-year guidance Historical ...
Message Board Posts | Ipsen SA ADR (OTCMKTS:IPSEY)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $IPSEY News Article - Onivyde Regimen Demonstrated Statistically Significant Improvemen | whytestocks | investorshangout | 11/09/2022 6:50:50 PM |
whytestocks: $IPSEY News Article - Ipsen and Marengo Therapeutics Announce Strategic Partnership to | whytestocks | investorshangout | 08/01/2022 4:35:54 PM |
Emylers: IPSEY Financials 07/16/2014 09:26:03 Ipsen S.A. Period Ending Total Revenue Cost of Revenue | Emylers | investorshangout | 07/16/2014 2:26:00 PM |
Stock_Tracker: Latest Ipsen S.A. ADR (IPSEY) Headlines Ipsen's net profit up by 6.4% in H1 2013 | Stock_Tracker | investorshangout | 03/10/2014 10:58:33 AM |
chartguy89: IPSEY 11.41 Stock Charts $IPSEY 1 Month Chart | chartguy89 | investorshangout | 03/08/2014 4:47:14 AM |
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...